Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Druckformat: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v14.i1.40
pages 57-77

Role for the cAMP-Protein Kinase A Signaling Pathway in Suppression of Antitumor Immune Responses by Regulatory T Cells

Sheraz Yaqub
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo; and Department of Gastroenterological Surgery, Akershus University Hospital, N-1478 Lørenskog, Norway
Kjetil Tasken
The Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, Norway

ABSTRAKT

CD4+CD25+ regulatory T (Treg) cells are engaged in the maintenance of immunological self-tolerance and suppressive control of excessive immune responses to foreign antigens. Furthermore, Treg cells infiltrate tumor tissues and may impede immune surveillance against cancer and hamper the development of an effective antitumor immunity. Depletion of Treg cells in animal models has been demonstrated to provoke tumor immunity. Attenuation of Treg-mediated suppression is therefore an interesting strategy to enhance antitumor responses. We recently found that adaptive Treg cells express COX-2 and suppress responder T cells in a PGE2-cAMP-dependent manner, which can be reversed by COX-2 inhibitors or EP-receptor antagonists. The same mechanism also appeared to be operative in patients with colorectal cancer where treatment with COX-inhibitor or cAMP-antagonist enhanced antitumor immune responses to the same extent as depletion of Treg cells. This provides mechanism-based opportunities for pharmacological intervention to interfere with Treg immunosuppression. In this review we will discuss key mechanisms used by Treg cells to suppress antitumor immunity, with emphasis on the cAMP-PKA pathway. We will also highlight some of the roles of Treg cells in cancer.


Articles with similar content:

Drug Combinations with HDAC Inhibitors in Antitumor Therapy
Critical Reviews™ in Oncogenesis, Vol.20, 2015, issue 1-2
Noemi Arrighetti, Cristina Corno, Laura Gatti
Recognition of Melanoma-Derived Antigens by CTL: Possible Mechanisms Involved in Down-Regulating Anti-Tumor T-Cell Reactivity
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Flavio Arienti, Alessandro Borsatti, Paola Squarcina, Chiara Castelli, Filiberto Belli, Ettore Appella, Francesca Rini, Douglas J. Loftus, Francesco M. Marincola, Giorgio Parmiani, Licia Rivoltini, Carsten Geisler
Driving Cytotoxic Natural Killer Cells into Melanoma: If CCL5 Plays the Music, Autophagy Calls the Shots
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Muhammad Zaeem Noman, Markus Ollert, Ludovic Menard, Malina Xiao, Bassam Janji, Martyna Szpakowska, Andy Chevigne, Guy Berchem, Manon Bosseler
Targeting NKG2D and NKp30 Ligands Shedding to Improve NK Cell−Based Immunotherapy
Critical Reviews™ in Immunology, Vol.36, 2016, issue 6
Marco Cippitelli, Alessandra Soriani, Alessandra Zingoni, Elisabetta Vulpis, Angela Santoni, Cinzia Fionda, Ilaria Nardone
Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies
Critical Reviews™ in Immunology, Vol.37, 2017, issue 1
Toshiaki Kikuchi, Toshiyuki Koya, Masashi Arita, Miho Takahashi, Yu Saida, Satoshi Watanabe